Celcuity (NASDAQ:CELC) Price Target Raised to $50.00

Key Points

• HC Wainwright raised Celcuity's price target to $50.00, up from $27.00, indicating a potential upside of 27.74% from the stock's previous close.
• Celcuity's stock experienced significant trading activity, with 22.8 million shares traded, pushing the price up to $39.14 during midday trading.
• Institutional investors hold approximately 63.33% of Celcuity's stock, with notable increases in holdings from firms such as Baker BROS. Advisors and Ameriprise Financial.

Celcuity (NASDAQ:CELC - Get Free Report) had its target price upped by equities research analysts at HC Wainwright from $27.00 to $50.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm currently has a "buy" rating on the stock. HC Wainwright's target price indicates a potential upside of 27.65% from the company's previous close. HC Wainwright also issued estimates for Celcuity's FY2026 earnings at ($3.88) EPS, FY2027 earnings at $0.81 EPS, FY2028 earnings at $4.05 EPS and FY2029 earnings at $7.13 EPS.

Other equities analysts also recently issued reports about the stock. Needham & Company LLC reiterated a "buy" rating and set a $29.00 price target on shares of Celcuity in a report on Monday. Stifel Nicolaus initiated coverage on shares of Celcuity in a report on Tuesday, July 1st. They issued a "buy" rating and a $30.00 price target for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $39.20.

Celcuity Price Performance

CELC stock traded down $1.13 during mid-day trading on Monday, hitting $39.17. The company had a trading volume of 1,601,001 shares, compared to its average volume of 530,503. The company has a 50-day moving average price of $14.09 and a 200 day moving average price of $11.89. Celcuity has a 12-month low of $7.57 and a 12-month high of $46.42. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -12.93 and a beta of 0.45. The company has a quick ratio of 6.61, a current ratio of 6.61 and a debt-to-equity ratio of 1.14.

Celcuity (NASDAQ:CELC - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.86) EPS for the quarter, beating the consensus estimate of ($0.95) by $0.09. On average, research analysts anticipate that Celcuity will post -2.62 earnings per share for the current year.

Insider Buying and Selling

In related news, Director David Dalvey sold 100,000 shares of the firm's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $43.98, for a total transaction of $4,398,000.00. Following the sale, the director owned 125,000 shares in the company, valued at approximately $5,497,500. This trade represents a 44.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 15.77% of the company's stock.

Institutional Trading of Celcuity

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Summit Investment Advisors Inc. grew its position in Celcuity by 49.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company's stock valued at $45,000 after buying an additional 1,132 shares during the period. Aquatic Capital Management LLC acquired a new stake in Celcuity during the fourth quarter valued at $50,000. AlphaQuest LLC grew its position in shares of Celcuity by 176.3% in the second quarter. AlphaQuest LLC now owns 7,087 shares of the company's stock valued at $95,000 after purchasing an additional 4,522 shares during the period. Focus Financial Network Inc. acquired a new stake in shares of Celcuity in the first quarter valued at about $108,000. Finally, Perkins Capital Management Inc. acquired a new stake in shares of Celcuity in the first quarter valued at about $115,000. Institutional investors and hedge funds own 63.33% of the company's stock.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.